Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical use and pharmaceutical composition of pyrroloquinoline quinine, its derivatives and/or its salts

a technology of pyrroloquinoline quinine and pharmaceutical composition, which is applied in the direction of drug composition, sexual disorder, organic chemistry, etc., can solve the problems of drug inability to be used for a long time, complete loss of endocrine function of ovarian function,

Inactive Publication Date: 2021-05-13
NANJING SHUPENG BIOTECH CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about the use of a substance called pyrroloquinoline quinone (PQQ) and its derivatives and salts to treat endometriosis. PQQ is a coenzyme found in bacteria and is widely distributed in plants and animals, including humans. It has various biological functions, including promoting growth, protecting against inflammation and oxidative damage, improving sleep and cognition, and serving as a nutrient for animal development and reproduction. The patent provides evidence that PQQ can inhibit the growth of endometrial cells and improve symptoms of endometriosis when combined with low doses of another substance called N-acetyl cysteine (NAC). The use of PQQ is better than currently available drugs for treating endometriosis, and it is safe and beneficial for fertility.

Problems solved by technology

Radical surgery has a good therapeutic effect, but need to remove the uterus and bilateral accessory, which makes women completely lost the endocrine function of ovarian function and fertility, so it is not suitable for patients of reproductive age.
So these drugs can not be used for a long time, which makes it harder to get pregnant during drug treatment.
Once these drugs are ceased, ectopic tissue is very likely to reappear.
The treatment of EM with NAC has obvious deficiency in clinical application.
Specifically, the stability of NAC in vivo is not high enough, so its antioxidant capacity is limited and a larger dose is required to ensure its efficacy.
As NAC is an acidic substance, taking NAC at such high dosage may cause digestive symptoms in some patients.
Moreover, according to the Pharmacopoeia of the People's Republic of China (2010 edition), NAC as a well-known expectorant has many other adverse reactions, even causes poisoning in some serious cases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical use and pharmaceutical composition of pyrroloquinoline quinine, its derivatives and/or its salts
  • Pharmaceutical use and pharmaceutical composition of pyrroloquinoline quinine, its derivatives and/or its salts
  • Pharmaceutical use and pharmaceutical composition of pyrroloquinoline quinine, its derivatives and/or its salts

Examples

Experimental program
Comparison scheme
Effect test

example 1

ited Proliferation of Endometrial Stromal Cell In Vitro

[0062]Ectopic endometrial tissue primarily consists of epithelial and stromal cells. The ability of proliferation and invasion of these two cells determines the severity of the disease caused by ectopic endometrium. In this Example, the stromal cells in ectopic endometrium were selected to study the inhibitory effect of PQQ on proliferation of endometrial stromal cells in vitro.

[0063]Materials and Methods

[0064]Isolation of Human Endometrial Stromal Cells

[0065]Endometrial tissues were surgically isolated from patients with chocolate cyst of ovary, washed 2 to 3 times with PBS supplemented with antibiotics in ultra-clean cabinet, and cut into tiny pieces (about 1 mm3 in size) with aseptic scissors. The tissues were digested with 1 mg / ml collagenase type I for 30 to 90 min at 37° C., and continually digested with Dnase I (final concentration of 15 U / ml, 2% Dnase I) for another 30 min. The digested tissues were filtered thorough 60-...

example 2

gistic with PQQ Inhibited Endometrial Stromal Cell Proliferation

[0077]Materials and Methods

[0078]Detection of Cell Proliferation

[0079]Primary ectopic endometrial stromal cells were cultured and the subcultured cells of the 3th to 6th passage were chosen as experimental subjects. The cells in logarithmic growth phase were lysed and incubated in the cell culture plate at a of 50˜60% (e.g. 2×104 cells / well). The cells grew adhering to the wall for 24 hours before being treated with drugs. The cells were divided into groups and each group was given different dose of PQQ. At indicated time point, 20 μL MIT (5 mg / ml in PBS, pH=7.4) was added to every well. The cells were then incubated in an incubator at 37° C. in a 5% CO2 atmosphere for 4 h. After terminating incubation, the culture supernatant in each cell was carefully aspirated away, but formazan crystals should not be aspirated away in any case. 150 μL DMSO was added to each well respectively. All the wells were shaken with Orbital s...

example 3

its Oxidative Stress Status in Endometrial Stromal Cells

[0085]Materials and Methods

[0086]Superoxide anion (O2.−) assay kit was purchased from Nanjing Jiancheng Bioengineering Insitute; Hydroxyl free radical assay kit was purchased from Shanghai Xinyu Biological Technology Co., Ltd.; Hydrogen Peroxide Assay Kit was purchased from Beyotime Biotechnology Research Institute.

[0087]Determination of Superoxide Anion (O2.−) Content

[0088]The cells were cultured in 96-well cell culture plates for 24 h after the cells adhered to the plate. Three different concentrations PQQ (30 nm, 300 nm and 3 um) were added to the culture medium respectively. After additional 18 h incubation, the culture medium was discarded, and fresh culture medium supplemented with NBT (a final concentration of 1 mg / mL) was added to the cells. The cells were continually cultured for another 1 h at 37° C. The cells were fixed with 100% methanol, and naturally dried. 120 μL KOH (2 mol / L) and 140 μL DMSO were added to the ce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of pyrroloquinoline quinine (PQQ), its derivatives and / or salts for the preparation of drugs for the treatment and / or prevention of endometriosis including adenomyosis, chocolate cyst of ovary, deeply infiltrating endometriosis and other type of endometriosis. In addition, the present invention relates to the use of PQQ in combination with one or more the following antioxidants: N-Acetyl-L-cysteine (NAC), resveratrol, epigallocatechin gallate, vitamin E or vitamin C for the preparation of drugs for inhibiting the proliferation, oxidative stress status, invasion and migration of endometrial stromal cell. The use of PQQ in combination with NAC shows a synergistic effect on inhibiting cell proliferation: significantly inhibiting the proliferation of endometrial stromal cell in vitro; significantly reducing the damaged size of tissue caused by endometriosis in vivo; significantly reducing the infiltration of endometrial stroma and glands; significantly reducing the dose of NAC as well. PQQ is beneficial for fertility, and increases the chances of getting pregnant. PQQ alone or PQQ in combination with NAC generally shows no side effects and will not interfere with pregnancy.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of the application U.S. Ser. No. 15 / 569,781, which was a national stage entry of a PCT application No. PCT / CN2016 / 079709 which was filed on Apr. 20, 2016, which claims priority of No. 201510206583.8 of the Chinese patent applications filed by the same applicant and inventor on Apr. 27, 2015, which is incorporated herein in its entirety by reference.FIELD OF THE INVENTION[0002]The invention relates to new pharmaceutical use and pharmaceutical composition of pyrroloquinoline quinine, its derivatives and / or its salts, and more specifically relates to use of pyrroloquinoline quinine (PQQ), its derivatives and / or its salts for the preparation of drugs for the treatment and / or prevention of endometriosis.BACKGROUND ART[0003]Endometriosis (EM) is a disease (or a series of lesions and symptoms) caused by the growth of viable endometrial tissue outside the uterine cavity, including adenomyosis, chocolate cyst of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4745A61K31/223A61P15/00A61K45/06
CPCA61K31/4745A61K31/223C07D471/04A61K45/06A61P15/00A61K2300/00
Inventor WEN, CHUANJUNSUN, FENYONG
Owner NANJING SHUPENG BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com